whoops wrong name but that's me.
Thanks, that's good news and we'll soon see if it's true.
Kittyface
not from earl, from earlier post by hr. jerry
"hepatitisresearcher
11/08/07
mremeet t\Testing the stored sera from the study visits for riba concentrations/compliance would allow to judge if the SOC control group was more lax in their riba habits. I dont think this was done, I would assume that there is the assumption that this noncompliance burden distributes evenly between the arms. If anything the real results would be even better if the existing results contained the element of noncompliance.. What seems to matter is the reliability of the SVR12 rate and they worked hard to assure excellent testing ( dual approach, that also serves to control false negs.).
Again, I was told, that not a single EOT neg patient in the NTZ group actually available for testing was found pos at post treat wk12. Like NTZ somehow prevents relapse by having reduced the invisible residual to ultralow levels in the UND treatment phase , because it keeps working at the residual because there is no real resistance to it oppositre as this might be the case with a drug that attaches to a viral protein? " ----I hope this means Alinia does have much resistance problems. jerry